@entity956 termination by overdrive transesophageal pacing and the facilitating effect of oral XXXX .

@entity1 @entity713 @entity956 @entity158 @entity943 @entity2779
Transesophageal overdrive atrial pacing is effective and safe for @entity956 . The influence of antiarrhythmic drug therapy on this procedure is controversial. In this study, we investigated whether oral @entity2779 may facilitate this procedure. Thirty @entity1 with @entity956 were randomized into 2 groups in which transesophageal pacing was attempted: group A, without treatment; and group B, after oral administration of @entity2779 600 mg. Transesophageal pacing was effective in interrupting @entity956 in 53% of @entity1 (8 of 15) in group A and in 87% of @entity1 (13 of 15) in group B. A significant lengthening of the flutter cycle was observed with respect to the baseline in @entity1 given @entity2779 (261 +/- 23 vs 217 +/- 25, p < 0.01). Sinus rhythm resumed at a shorter paced cycle in group A @entity1 (166 +/- 13 vs 187 +/- 14 ms, p < 0.01). The transesophageal threshold for stable atrial capture was significantly lower in group A (20.5 +/- 0.2 vs 23.3 +/- 1.2, p < 0.01). In no @entity1 was the threshold for atrial capture higher than the @entity158 threshold. We did not observe abrupt enhancement of @entity713 . We conclude that @entity2779 is effective and safe when used with transesophageal pacing in the termination of @entity956 . The slowing effect of the drug on intraatrial conduction and the possible stabilizing effect on the reentry circuit appear to be outweighed by the positive effect of @entity2779 on the excitable gap of the circuit, facilitating its capture and accounting for the beneficial effect of the drug on @entity943 termination.
